Showing results (41-50 of 76) with videos related to
Sort By:
Pageof 8
Current Oncology (Toronto, Ont.)|May 15, 2023
Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC TrialJenny J Ko, Shantanu Banerji, Normand Blais, et al.Clinical Colorectal Cancer|December 4, 2014
Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancerRenata D'Alpino Peixoto, Aalok Kumar, Caroline Speers, et al.Lung Cancer (Amsterdam, Netherlands)|May 13, 2026
Consensus recommendations on surveillance and survivorship for patients with unresectable/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian expertsJenny J Ko, Normand Blais, Anthony Brade, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 13, 2023
Evaluating the childcare needs of cancer patients undergoing radiation therapyZhang Hao Jim Li, Kenzie MacDonald, Katherine Preston, et al.JTO Clinical and Research Reports|May 2, 2022
Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief ReportMarie-Hélène Denault, Shelley Kuang, Aria Shokoohi, et al.Frontiers in Oncology|February 11, 2026
TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterationsThomas Newsom-Davis, Barbara Melosky, Rebecca S Heist, et al.The Oncologist|August 30, 2020
Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung CancerBarbara Melosky, Parneet K Cheema, Anthony Brade, et al.Current Oncology (Toronto, Ont.)|August 25, 2023
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 ExpressionMarie-Hélène Denault, Jamie Feng, Shelley Kuang, et al.International Journal of Cancer|June 20, 2024
Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancerBarbara Melosky, Mark D Vincent, Anna L McGuire, et al.Therapeutic Advances in Medical Oncology|November 22, 2021
The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancerBarbara Melosky, Parneet Cheema, Rosalyn A Juergens, et al.Pageof 8